Supplementary figures - Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma
figure
posted on 2022-04-29, 08:29 authored by Ninad Shah, Ali Mojebi, Dieter Ayers, Shannon Cope, Sujith Dhanasiri, Faith E. Davies, Parameswaran Hari, Payal Patel, Kristen Hege, Devender DhandaSupplemental figure 1. HRs of OS for ide-cel versus conventional care based on the triple- or quad-refractory population from MAMMOTH.
Supplemental figure 2. HRs of OS for ide-cel versus conventional care based on the penta-refactory population from MAMMOTH.